The Pharmaceutical-Grade Hawthorn 2026 H2 Sourcing Guide — Ph. Eur. Crataegi Spec, EMA Reality, and FairWild Wildcraft for EU Industrial Buyers

Procurement teams sourcing hawthorn (*Crataegus*) into Europe in 2026 are working in a category where the regulatory reality and the marketing reality have drifted apart further than in any other botanical we broker. The on-pack "EMA-approved heart failure treatment" claim that runs through the supplement aisle is, on regulator review, a substantially weaker assertion than the marketing copy suggests. The "Crataegus oxyacantha" name still circulating on many B2B catalogues is taxonomically rejected. The "Bulgaria Rhodope FairWild wildcraft" sourcing story is partially documented, partially marketing extrapolation. This guide is the pharmaceutical-grade hawthorn sourcing reference for an EU industrial buyer — what the European Pharmacopoeia and EMA actually specify, what the most-studied extract (WS 1442) actually achieved in the SPICE clinical trial, and where the Carpathian + Rhodope supply chain actually sits.

The taxonomy that the European Pharmacopoeia and EMA actually use

The two pharmacopoeial preparations that an EU industrial buyer should write into a specification are Crataegi folium cum flore (dried flowering tops — leaf and flower together) and Crataegi fructus (the dried fruit, commonly called the berry). The European Pharmacopoeia and the [EMA HMPC monograph](https://www.ema.europa.eu/en/medicines/herbal/crataegi-folium-cum-flore) define both preparations as covering *Crataegus monogyna* Jacq. (Lindm.), *Crataegus laevigata* (Poir.) DC., and their hybrids. The [2025 EMA draft revision](https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-crataegus-monogyna-jacq-lindm-c-laevigata-poir-dc-or-their-hybrids-c-pentagyna-waldst-et-kit-ex-willd-c-azarolus-l_en.pdf) of the monograph (consultation 15 April – 15 July 2025) extends the scope further to include *Crataegus pentagyna* Waldst. et Kit. ex Willd. and *Crataegus azarolus* L. The regulator's direction is therefore toward combined species coverage, not species purity — a sourcing specification that insists on single-species *C. monogyna* lots is operating outside the pharmacopoeial framework that defines the active material.

Two taxonomy items belong on a buyer's procurement red-flag list. First, the name "Crataegus oxyacantha" is taxonomically rejected — the European pharmacopoeial and ethnobotanical literature now consolidates it under *C. laevigata*, but B2B catalogues continue to ship under the old name. A COA naming "*C. oxyacantha*" against modern pharmacopoeial spec is a supplier-side QC quality signal. Second, Crataegus pinnatifida — the Chinese hawthorn used in traditional Chinese medicine ("Shan Zha") — sits outside the European Ph. Eur. monograph. Material shipped under "hawthorn berry" labelling from Chinese origin is not pharmacopoeial-grade European hawthorn ([PMC9498108](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498108/)), and a downstream buyer needs to know that distinction before writing a Ph. Eur.-compliance contract.

Ph. Eur. specifications — what an EU industrial buyer actually contracts against

The European Pharmacopoeia spec for *Crataegi folium cum flore* sets minimum total flavonoid content at 1.5% expressed as hyperoside on the dried herb. The aqueous extract minimum is 2.5% total flavonoid (hyperoside-equivalent). The hydroalcoholic extract minimum is 6% total flavonoid (hyperoside-equivalent). These are the contractual chemistry anchors for a pharmaceutical-grade specification — every step up the extraction ladder raises the flavonoid floor in a defined way ([EMA assessment report on Crataegus spp. folium cum flore](https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-crataegus-spp-folium-cum-flore_en.pdf); [Altmeyers Phytotherapy Encyclopedia](https://www.altmeyers.org/en/naturopathy/crataegi-folium-cum-flore-143281)).

For the dried fruit (*Crataegi fructus*), the European Pharmacopoeia identifies the dominant marker compound as B-type oligomeric procyanidins (OPC), with a quantitative flavonoid floor that is preparation-specific rather than berry-blanket. Peer-reviewed work on the hydroalcoholic flowering-tops extract reports flavonoid sub-component distributions including hyperoside (12.9%), vitexin (0.9%), isovitexin (2.5%), isoquercitrin (6.0%) — with total flavonoid content up to 2% in the dried herb, and oligo- plus polymeric B-type procyanidins around 3% ([Phytomedicine procyanidin quantification](https://www.sciencedirect.com/science/article/abs/pii/S0367326X15001008); [variability study in Crataegi folium cum flore](https://www.sciencedirect.com/science/article/abs/pii/S221478611930498X)). An EU industrial buyer writing a pharmaceutical-grade specification therefore contracts against HPLC-quantified total flavonoid floor + the procyanidin profile, with the preparation form (raw flowering tops / aqueous extract / hydroalcoholic extract) defining which floor applies.

WS 1442 — the most-studied extract, and what the SPICE trial actually showed

The dominant pharmaceutical-grade hawthorn extract is WS 1442, a hydroalcoholic dry extract of *Crataegi folium cum flore* with a Drug-Extract Ratio (DER) of 4 to 6.6 : 1, extracted with 45% (w/w) ethanol, standardised to 17.3–20.1% oligomeric procyanidins. WS 1442 is the active ingredient of the Crataegutt® novo / CardioMax® preparations marketed by Schwabe; it is the most-studied hawthorn extract in cardiovascular indications and the spec against which most peer-reviewed clinical data was generated ([benefit-risk assessment of WS 1442, Am J Cardiovasc Drugs 2017](https://pmc.ncbi.nlm.nih.gov/articles/PMC5772138/); [J Physiol Pharmacol 2017 review](https://www.jpp.krakow.pl/journal/archive/08_17/articles/03_article.html)).

The 2008 Cochrane meta-analysis (Pittler / Guo / Ernst) reviewed 14 randomised controlled trials — 11 on WS 1442, 3 on the alternative extract LI 132 — and concluded that hawthorn-extract monotherapy produced significant improvement in exercise tolerance and symptoms in heart-failure populations ([Cochrane Library record](https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005312.pub2/information); [PubMed 18254076](https://pubmed.ncbi.nlm.nih.gov/18254076/)). The SPICE trial (n=2,681, NYHA II–III, 24 months, modern HF therapy with WS 1442 add-on) tested a harder endpoint: a composite of sudden cardiac death, progressive HF death, fatal/non-fatal MI, and HF hospitalisation. On that composite mortality endpoint, WS 1442 did not produce significant benefit; the safety profile was good. The marketing claim "EMA-approved heart failure treatment" is therefore a meaningful overstatement of the regulatory and clinical evidence base. The accurate framing for a buyer-facing document is: EMA HMPC traditional-use monograph for heart-related complaints associated with nervousness, mild mental stress, and to aid sleep — not heart-failure cure.

EMA monograph status — traditional-use, not well-established

The EMA HMPC monograph on *Crataegi folium cum flore* sits in the traditional-use category, which under the EU herbal medicinal products framework requires a documented history of medicinal use of at least 30 years total and at least 15 years inside the EU. That bar is met; the well-established-use bar (which would require Cochrane-grade clinical efficacy evidence) is not. The single-Member-State exception is Germany and Austria, where WS 1442 holds well-established-use authorisation as add-on therapy in NYHA II mild heart failure — but those are national authorisations, not centralised EMA approvals. A specification or downstream finished-product positioning that says "EMA-authorised for heart failure" therefore conflates the German/Austrian national pathway with the EU central monograph status. The defensible language for an EU industrial buyer is the traditional-use framing on the EU-central side, with the WS 1442 NYHA II evidence cited as the well-established Member-State case.

On the EFSA Article 13 health-claims register, hawthorn — together with roughly 1,548 botanical claims — has been on the on-hold register since 2010 ([EU register of health claims](https://food.ec.europa.eu/food-safety/labelling-and-nutrition/nutrition-and-health-claims/eu-register-health-claims_en); [Vitafoods Insights on-hold botanical claims](https://www.vitafoodsinsights.com/regulations/on-hold-botanical-claims-inch-closer-to-full-assessment-by-the-eu)). Under Regulation 1924/2006 Article 28(5) transitional measures, those claims remain legally usable but are technically unstable — the Commission can reach a final decision at any time. A buyer's downstream marketing strategy that depends on an EFSA-authorised hawthorn health claim is therefore building on a transitional foundation, not a final authorisation.

Forms, grades, and the wildcraft vs cultivated split

The commercial hawthorn supply chain runs on three preparation forms: dried whole or crushed Crataegi fructus (the berry, used for nutraceutical teas, supplement powders, and tincture preparations); whole or fragmented dried Crataegi folium cum flore (the flowering tops, the pharmaceutical-grade raw material that the EMA monograph and WS 1442 spec are written against); and standardised hydroalcoholic dry extract at the WS 1442 DER + OPC standardisation profile. The phytomedicine trade's principal source geographies are documented as Albania, Bulgaria, Romania, the former Yugoslavia, and Poland.

The FairWild Foundation lists hawthorn as a certifiable wild-collected ingredient, with the pharmacopoeial preparations *Crataegi folium cum flore* and *Crataegi fructus* explicitly in scope ([FairWild hawthorn ingredient profile](https://www.fairwild.org/ingredients/hawthorn)). The certified operator profile that the public registry surfaces is Phytopharm-trade LLC — based in Ukraine, not Bulgaria ([FairWild Phytopharm participants](https://www.fairwild.org/all-fairwild-participants/phytopharm)). A Tandor procurement engagement that promises "Rhodope FairWild" without first verifying the FairWild operator database for the specific region runs the same risk that we have flagged elsewhere on aronia and sea-buckthorn marketing claims — saying more than the registry can defend. The defensible sourcing posture for an EU industrial buyer is: Romanian Carpathian wild collection and Albanian / Bulgarian wildcraft tradition (documented in agricultural and ethnobotanical literature) ↔ FairWild-certified operator status verified against the FairWild registry case by case, not assumed by region.

Harvest windows and 2026 H2 procurement timing

The fenology splits cleanly into two windows. Crataegi folium cum flore — the flowering tops — is harvested during a narrow 2–3 week flowering window in May–June. For an H2 2026 sourcing brief, the 2026 flowering-tops harvest is already in. New raw-material allocation is therefore against either residual 2026 stock or forward 2027 contract — a buyer needing 2026-vintage material against an EMA-grade extract specification should be pre-booking 2027 already.

Crataegi fructus — the berry — has a much longer harvest window of September through November, with berries sweetening after first frost and remaining on the branch into early winter. This is the harvest window that aligns with H2 2026 procurement: the 2026 berry crop opens against the same procurement cycle in which this guide is published. For organic-certified pharmaceutical-grade allocation, pre-booking 3–4 months ahead of the September window is the standard pattern. The 2024 Polish frost event — well documented in regional agricultural press — established that single-region weather variability remains the dominant supply-side risk; dual-sourcing Polish base supply with Carpathian wildcraft is the practical hedge.

Heavy-metal, pesticide, and microbiological compliance

Hawthorn berries, flowering tops, and extracts are covered by the general food and herbal-tea categories under EU Regulation 2023/915 (effective 25 May 2023), which replaced the previous Reg 1881/2006 framework for contaminants ([EUR-Lex 2023/915](https://eur-lex.europa.eu/eli/reg/2023/915/oj/eng)). Maximum levels for lead, cadmium, mercury, arsenic, and nickel are category-specific. A technical detail that buyers should note: maximum levels in food supplements are written against the ready-to-use supplement, not the raw botanical, but Regulation 396/2005's pesticide MRLs are written against the raw plant categories ("fruits" for *Crataegi fructus*, "herbal infusions" for *Crataegi folium cum flore*). A pharmaceutical-grade specification therefore requires per-shipment COA on both heavy metals and pesticide residue panels, with the raw-material category explicitly documented. Microbiological criteria for processed product chains are governed separately by Regulation 2073/2005.

How TANDOR sources hawthorn for a 2026 H2 specification

Tandor is an EU-organic botanical sourcing broker based in Suceava, Romania, with active coverage across the documented Romanian Carpathian, Albanian, and Polish hawthorn production base. For a 2026 H2 hawthorn procurement engagement the brief covers form (*Crataegi folium cum flore* / *Crataegi fructus* / standardised hydroalcoholic dry extract), preparation specification (Ph. Eur. flavonoid floor for the relevant preparation form; for extract product, DER and OPC standardisation against the WS 1442 reference profile), volume, harvest-year vintage (2026 fructus pre-book vs 2026 folium-cum-flore residual vs 2027 forward), EU-Organic operator certificate identifier, EU Reg. 2023/915 heavy-metal COA, pesticide residue panel under Reg. 396/2005, microbiological panel under Reg. 2073/2005, FairWild operator status where wildcraft sourcing is required, delivery point and Incoterm.

Tandor returns multi-supplier comparisons with verified pharmacopoeial-grade documentation, sample dispatch coordination, COA collection per shipment, and DDP delivery support. Tandor is currently in pre-launch — sourcing intros, RFQ qualification, sample dispatch coordination, and DDP logistics are all free during this phase. Transparent commercial terms publish with the formal commercial offering opening later this year.

For Q3 and Q4 2026 hawthorn procurement the cleanest starting point is a written buyer brief sent to info@tandor.eu. The honest hawthorn sourcing position is straightforward: contract against the European Pharmacopoeia flavonoid floor and the WS 1442 OPC standardisation reference, frame the regulatory status in EMA HMPC traditional-use terms rather than as a heart-failure cure, verify FairWild operator status against the registry by name rather than by region, and treat the 2026 berry harvest pre-book and the 2027 flowering-tops forward as two separate procurement decisions with two separate timelines. That is the discipline that keeps a downstream pharmaceutical-grade or nutraceutical-grade product line legally defensible while the EMA monograph revision and the EFSA on-hold register continue to move.

---

*This guide draws on the EMA HMPC Crataegi folium cum flore overview and final assessment report, the 2025 EMA draft revised monograph (consultation April–July 2025), the European Pharmacopoeia flavonoid specifications via the Altmeyers Phytotherapy Encyclopedia summaries, the Phytomedicine and ScienceDirect peer-reviewed flavonoid and procyanidin quantification work, the PMC benefit-risk assessment of WS 1442 (Am J Cardiovasc Drugs 2017), the Cochrane 2008 meta-analysis (Pittler/Guo/Ernst), the SPICE trial reporting (PubMed/Medscape), EUR-Lex (Regulations 2023/915 + 396/2005 + 2073/2005 + 1924/2006 + Implementing 2021/1165 + Reg 2018/848), the EFSA on-hold botanical claims register, the FairWild Foundation ingredient and participant registries, and the Mountain Rose Herbs Bulgarian wildcraft travel reporting. Marketing claims of "25× blueberry antioxidant", "EMA-approved heart failure treatment", and unverified "Crataegus oxyacantha" species nomenclature are not supported by the cited peer-reviewed and regulatory sources and have been deliberately excluded.*